Pulmonx Corporation (LUNG) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pulmonx Corporation (LUNG:NASDAQ), powered by AI.

Current Price
$1.25
P/E Ratio
-0.9
Market Cap
51M
Sector
Healthcare
What is the Pulmonx Corporation stock price forecast?

Pulmonx Corporation is currently trading at $1.25. View real-time AI analysis on Alpha Lenz.

What is Pulmonx Corporation insider trading activity?

View the latest insider trading data for Pulmonx Corporation on Alpha Lenz.

What is Pulmonx Corporation's P/E ratio?

Pulmonx Corporation's P/E ratio is -0.9.

Pulmonx Corporation

NASDAQ · LUNG
$1.25-0.03(-2.34%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Pulmonx Corporation's future dividend policy...
Alpha Chat Insight

Pulmonx Corporation trades at a P/E of -0.9 (undervalued) with modest ROE of -77.2%. 3Y revenue CAGR of 19.0% highlights clear growth momentum.

Ask for details

Company Overview

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.

CEOMr. Steven S. Williamson
SectorHealthcare
IndustryMedical Devices
Employees7,859

Company Statistics

FY 2025

Profile

$50.86MMarket Cap
$90.50MRevenue
0.00Shares Out
7,859Employees

Margins

74.19%Gross
-54.33%EBITDA
-59.30%Operating
-58.98%Pre-Tax
-59.67%Net

Valuation

-0.94P/E
0.94P/B
0.56EV/Sales
-0.76EV/EBITDA
-1.55P/FCF

Growth (CAGR)

19.03%Rev 3Yr
22.55%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-36.97%ROA
-77.19%ROE
-34.38%ROIC

Financial Health

$69.75MCash & Cash Equivalents
$5.42MNet Debt
138.91%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pulmonx Corporation (ticker: LUNG) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 7,859 employees. Market cap is $51M.

The current price is $1.25 with a P/E ratio of -0.94x and P/B of 0.94x.

ROE is -77.19% and operating margin is -59.30%. Annual revenue is $90M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pulmonx Corporation (LUNG) Stock Forecast 2026 $1.25 — Price, Financials & Analyst Targets | Alpha Lenz